Professor Karl Moore of the Desautels Faculty of Management at McGill University with Talking Management for the Globe and Mail sits down in Vancouver with Sheen Levine, from the University of Texas at Dallas and Columbia University.
POXEL SA (Euronext - POXEL - FR0012432516), a clinical-stage biopharmaceutical company focused on the development of novel treatments for type 2 diabetes and metabolic disease, today announced that Pierre Legault has been appointed the new Chairman of the Board of Directors. Mr. Legault joined Poxel's Board of Directors in February 2016 and will succeed Dr. Thierry Hercend, who will continue to support Poxel as a member of its Board.
CablePlan Plannica reduces the planning cycle from days to minutes. It enhances and improves the decision making of production planners. CablePlan reduces the manual workload and releases the decision makers’ valuable time, enabling them to regain responsiveness and flexibility in the planning cycle. CablePlan enables planners to increase their planning horizon, enables smarter optimization and allows planning considering multiple objectives.
According to Forbes, there are “three major disconnects” that “prevent business schools, especially those with full-time MBA programs,” from developing leaders. Topping the list is a lack of sufficient emphasis on soft “people” skills, Henry Mintzberg, Cleghorn Professor of Management Studies at the Desautels Faculty of Management, McGill University, told the magazine.
What started as a series of mishaps while flying with United Airlines 20 years ago will culminate Friday in a McGill University professor and one of the world’s largest passenger carriers facing off in a Montreal courtroom.
United Continental Holdings Inc. is suing Jeremy Cooperstock, an engineering professor at McGill, over his customer complaint website, Untied.com. The airline wants Cooperstock to delete contact information for its management and lawyers; he has refused.
Pierre Legault a rejoint Poxel en apportant plus de 35 ans d’expérience de l’industrie biotechnologique et pharmaceutique. Il est membre du Conseil d’Administration de Tobira Therapeutics (Président du Comité d’Audit), de ceux d’Iroko Pharmaceuticals et de NephroGenex. Au cours de sa carrière, M. Legault a été Président, Directeur Général et Directeur Financier de plusieurs sociétés cotées incluant Eckerd Pharmacies, NephroGenex, OSI Pharmaceuticals et Rite Aid. Il a occupé plusieurs fonctions seniors chez Sanofi-Aventis et sociétés précédentes. M.